Navigation Links
Despite ongoing safety concerns, study finds adverse reactions from contrast agents rarely occur
Date:9/20/2009

Iodinated and Gadolinium based contrast agents, frequently used during computed tomography (CT) and MRI scans to aid in the imaging process, are associated with a very low rate of adverse effects, according to a large cohort study published in the October issue of the American Journal of Roentgenology (AJR).

The study, performed at the Mayo Clinic in Rochester, MN, included a total of 456,930 contrast doses administered. "Only 522 cases of adverse effects were identified," said Christopher H. Hung, MD, lead author of the study. "The overwhelming majority of adverse effects were mild, represented with nausea and vomiting and mild rash. Only 16 cases necessitated transfer for further observation and treatment," he said.

"Contrast agents are very safe to use and they are often essential in aiding the diagnosis of CT and MR studies. As our study suggests, with the advent of newer contrast agents we have been able to improve their power-ability and safety profile," said Dr. Hunt.

"While contrast reactions can occur, it is important to note that they are rarely severe. Most of the reactions we saw in our study were mild and did not require treatment other than observation and supportive care," he said.


'/>"/>

Contact: Heather Curry
hcurry@acr-arrs.org
703-390-9822
American Roentgen Ray Society
Source:Eurekalert

Page: 1

Related medicine news :

1. Nick Jonas: Livin the Dream Despite Diabetes
2. Despite H1N1 Flu Threat, Most Americans Havent Increased Hand Washing
3. Most Americans Continue to Support Moving Ahead With Health Care Reform Now Despite Town Hall Fights and Ad Campaigns
4. TeleHealth Services Continues to Grow Customer Base Despite Economys Impact on Healthcare Industry
5. 100+ Nurses to Rally in SF Wed. to Demand Stronger Swine Flu Safety Protections: California Hospitals Remain Unprepared Despite First Nurse Death
6. Despite Attacks, A.L.L. Calls on Catholic Organizations to Condemn Obamacare
7. WIN Global Poll Finds Concern Of Swine Flu Decreasing Despite Not Being Prepared For A Pandemic
8. Fat Reduction Market in Europe to Soar Despite Economic Downturn
9. Growth Despite Economy; Mainstreet Property Group Named One of Indiana's Fastest Growing Companies
10. JBFCS Surpasses Fundraising Goal For Hudson Valley Bike Ride Despite Difficult Financial Times
11. Despite More Tests, Some Arent Getting Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution ... the emergency ambulance transport experience for the millions of people who require these ... disrupted the taxi industry through the use of technology. Now, SmartEMS has put ...
(Date:6/26/2016)... ... ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect Plugin ... whole new perspective by using the title layers in ProSlice Levels to split-up ... Levels contains over 30 Different presets to choose from. FCPX users can ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , ... Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , ... our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
(Date:6/25/2016)... ... 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s ... setting the bar too high can result in disappointment, perhaps even self-loathing. However, those ... goal. , Research from PsychTests.com reveals that behind the tendency to ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... -- One of Australia,s successful biotechnology scientists, ... new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). ... list on the ASX. Noxopharm is a clinic-ready company ... Phase 1 clinical study later this year. ... biggest problems facing cancer patients - the ability of cancers to ...
(Date:6/26/2016)... June 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as ... Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) ... Daylight Time). As previously announced on May ... definitive merger agreement under which Jazz Pharmaceuticals has commenced ...
(Date:6/26/2016)... 27, 2016  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ... whatever measures required to build a strong and stable ... currently listed on the OTC Markets-pink current trading platform. ... CEO, "We are seeing an anomaly in market trading ... only by the Company, but shareholders and market players ...
Breaking Medicine Technology: